- Home
- RNST vs DNLI Comparison
RNST vs DNLI Comparison
Compare RNST & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNST | DNLI |
|---|---|---|
| Founded | 1904 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 1997 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RNST | DNLI |
|---|---|---|
| Price | $42.80 | $25.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $43.00 | $34.33 |
| AVG Volume (30 Days) | 769.6K | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.72 | N/A |
| Revenue Next Year | $4.67 | $408.85 |
| P/E Ratio | $45.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.04 | $12.58 |
| 52 Week High | $44.00 | $26.80 |
Technical Indicators
Market Signals| Indicator | RNST | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 74.24 |
| Support Level | $39.10 | $18.07 |
| Resistance Level | $43.50 | N/A |
| Average True Range (ATR) | 0.90 | 1.15 |
| MACD | 0.03 | 0.24 |
| Stochastic Oscillator | 67.62 | 83.50 |
Price Performance
Historical ComparisonAbout RNST Renasant Corporation
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.